Hodgkin Lymphoma News and Research

RSS

4SC commences treatment in its resminostat Phase II trial for HL

4SC AG, a drug discovery and development company focused on autoimmune and cancer indications, today announced the treatment of the first patient in a Phase II study evaluating resminostat (4SC-201), an oral pan-histone-deacetylase (HDAC) inhibitor in relapsed or refractory Hodgkin's Lymphoma (HL) patients.

12 Jan 2010

Canadian Cancer Society calls on the B.C. government to ban cosmetic use of pesticides

The Canadian Cancer Society British Columbia and Yukon today called on the B.C. government to enact legislation to ban the cosmetic use of pesticides that would set a new national standard. The Society is also asking British Columbians to participate in the on-line public consultation.

8 Jan 2010

Scott & White's CRI launches two clinical trials targeting cancers

Scott & White's Cancer Research Institute (CRI) has launched two clinical trials targeting cancers that affect both adults and children.

6 Jan 2010

A properly managed metabolic detoxification program can benefit

“Detox” programs have been in the spotlight recently, with a bevy of Hollywood celebrities citing their “detox” programs as the secret to looking great on the red carpet. But, what exactly is detoxification? Is it merely the latest health and beauty fad, or is it a true health therapy? And can anyone besides the Hollywood elite benefit from it?

22 Dec 2009

Cell Therapeutics supports Code on Interactions with Healthcare Professionals

Cell Therapeutics, Inc. announced today its support of the Pharmaceutical Research Manufacturers of America's (PhRMA) "Code on Interactions with Healthcare Professionals, revised July 2008" (PhRMA Code). Adherence to the Code is voluntary for commercial biotechnology and pharmaceutical companies.

22 Dec 2009

CD20 deficiency in humans results in impaired T cell-independent antibody responses

Antibodies directed against the protein CD20, which is expressed by immune cells known as B cells, are used to treat B cell non-Hodgkin lymphoma and rheumatoid arthritis.

22 Dec 2009

EMEA grants orphan drug designation for pixantrone in Europe

Cell Therapeutics, Inc. ("CTI") announced today that the European Medicines Agency (EMEA) has granted pixantrone orphan drug designation for the treatment of DLBCL which accounts for about 80% of aggressive non-Hodgkin's lymphoma.

21 Dec 2009

ODAC to review Cell Therapeutics' NDA for pixantrone

Cell Therapeutics, Inc. (CTI) announced today that on February 10, 2010 the U.S. Food and Drug Administration's Oncologic Drugs Advisory Committee (ODAC) will review the New Drug Application (NDA) for pixantrone for the treatment of relapsed/refractory aggressive non-Hodgkin's lymphoma (NHL).

17 Dec 2009

Cancer Research UK's phase I trial results of CHT25 published in Clinical Cancer Research

TWO THIRDS of Hodgkin's lymphoma patients treated with an experimental radioactive cancer therapy responded well to the treatment, reveal the results of a Cancer Research UK phase I trial published in Clinical Cancer Research, today (Tuesday).

16 Dec 2009

Seattle Genetics announces collaboration to globally develop and commercialize brentuximab vedotin

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today jointly announced that Seattle Genetics and Millennium have entered into an agreement to globally develop and commercialize brentuximab vedotin (SGN-35).

15 Dec 2009

Zevalin clinical data presented at 2009 ASH meeting

Spectrum Pharmaceuticals, Inc., a commercial stage biotechnology company with a primary focus in oncology, today announced that clinical data on ZEVALIN (ibritumomab tiuxetan) was presented at the 51st Annual Meeting of the American Society of Hematology (ASH), which was held December 5-8, 2009 at the Ernest N. Morial Convention Center in New Orleans, Louisiana.

11 Dec 2009

Genentech terminates dacetuzumab collaboration agreement with Seattle Genetics

Seattle Genetics, Inc. today reported that it has been notified by Genentech, a wholly owned member of the Roche Group, that Genentech has elected to terminate the companies’ collaboration agreement for dacetuzumab (SGN-40). Dacetuzumab is a monoclonal antibody targeting CD40 that has been investigated in clinical trials for non-Hodgkin lymphoma and multiple myeloma.

11 Dec 2009

VERTICAL Phase II trial results for NHL released

The Takeda Oncology Company today reported data from a clinical trial evaluating a VELCADE based combination for patients with relapsed/refractory non-Hodgkin’s lymphoma (NHL).

9 Dec 2009

Data evaluating combination therapy with REVLIMID and rituximab in patients with NHL presented

Celgene International Sàrl announced that investigational data evaluating combination therapy with REVLIMID (lenalidomide) and rituximab in patients with indolent non-Hodgkin’s lymphoma (NHL) were presented during the 51st American Society of Hematology’s annual meeting in New Orleans, LA.

9 Dec 2009

GSK updates long-term survival data of BEXXAR Therapeutic Regimen for Non-Hodgkin's lymphoma

GlaxoSmithKline announced today updated long-term survival data from two Phase II studies of BEXXAR® (tositumomab and iodine I-131 tositumomab) used in either patients with previously untreated cancer of the immune system (follicular lymphoma) or in patients with cancer of the lymphocytes (non-Hodgkin's lymphoma, NHL) that no longer responded to rituximab.

9 Dec 2009

Updated clinical data of Calistoga Pharmaceuticals’ delta selective PI3K inhibitor presented

Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced updated clinical data on CAL-101, the Company’s oral, delta selective PI3K inhibitor, presented during two oral presentations at the 51st American Society of Hematology Annual Meeting in New Orleans.

8 Dec 2009

ImmunoGen's SAR3419 holds hope for B-cell non-Hodgkin’s lymphoma

ImmunoGen, Inc., a biopharmaceutical company that develops targeted anticancer therapeutics, today announced the presentation of encouraging initial clinical findings with SAR3419 at the American Society of Hematology (ASH) 51st Annual Meeting and Exposition. Among the findings reported were responses to SAR3419 – administered as a single agent – among patients with B-cell non-Hodgkin's lymphoma that is refractory to treatment with rituximab (Rituxan®).

8 Dec 2009

Gloucester Pharmaceuticals to be acquired by Celgene

Celgene Corporation and Gloucester Pharmaceuticals Inc., a privately held pharmaceutical company, announced a definitive merger agreement under which Celgene Corporation will acquire Gloucester Pharmaceuticals. Celgene says the acquisition will continue to advance its leadership position in the development of disease-altering therapies through innovative approaches for patients with rare and debilitating blood cancers.

7 Dec 2009

Encouraging data from Seattle Genetics' phase I trial of brentuximab vedotin

Seattle Genetics, Inc. today reported data from a phase I weekly-dosing clinical trial of brentuximab vedotin (SGN-35), an antibody-drug conjugate (ADC), including multiple complete and partial remissions in patients with relapsed or refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma (ALCL).

7 Dec 2009

Micromet to present new data from its blinatumomab Phase 1 trial at the ASH meeting

Micromet, Inc., a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced the publication of a poster with new data from its ongoing phase 1 clinical trial of its product candidate blinatumomab in patients with non-Hodgkin's lymphoma (NHL) at the 51ST Annual Meeting of the American Society of Hematology (ASH) in New Orleans, Louisiana.

7 Dec 2009

Hodgkin Lymphoma News and Research

4SC commences treatment in its resminostat Phase II trial for HL

Canadian Cancer Society calls on the B.C. government to ban cosmetic use of pesticides

Scott & White's CRI launches two clinical trials targeting cancers

A properly managed metabolic detoxification program can benefit

Cell Therapeutics supports Code on Interactions with Healthcare Professionals

CD20 deficiency in humans results in impaired T cell-independent antibody responses

EMEA grants orphan drug designation for pixantrone in Europe

ODAC to review Cell Therapeutics' NDA for pixantrone

Cancer Research UK's phase I trial results of CHT25 published in Clinical Cancer Research

Seattle Genetics announces collaboration to globally develop and commercialize brentuximab vedotin

Zevalin clinical data presented at 2009 ASH meeting

Genentech terminates dacetuzumab collaboration agreement with Seattle Genetics

VERTICAL Phase II trial results for NHL released

Data evaluating combination therapy with REVLIMID and rituximab in patients with NHL presented

GSK updates long-term survival data of BEXXAR Therapeutic Regimen for Non-Hodgkin's lymphoma

Updated clinical data of Calistoga Pharmaceuticals’ delta selective PI3K inhibitor presented

ImmunoGen's SAR3419 holds hope for B-cell non-Hodgkin’s lymphoma

Gloucester Pharmaceuticals to be acquired by Celgene

Encouraging data from Seattle Genetics' phase I trial of brentuximab vedotin

Micromet to present new data from its blinatumomab Phase 1 trial at the ASH meeting

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News